Authors: Seefeld, MA Miller, WH Newlander, KA Burgess, WJ Payne, DJ Rittenhouse, SF Moore, TD DeWolf, WE Keller, PM Qiu, XY Janson, CA Vaidya, K Fosberry, AP Smyth, MG Jaworski, DD Slater-Radosti, C Huffman, WF

Citation: Ma. Seefeld et al., Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents, BIOORG MED, 11(17), 2001, pp. 2241-2244

Authors: Miller, WH Alberts, DP Bhatnagar, PK Bondinell, WE Callahan, JF Calvo, RR Cousins, RD Erhard, KF Heerding, DA Keenan, RM Kwon, C Manley, PJ Newlander, KA Ross, ST Samanen, JM Uzinskas, IN Venslavsky, JW Yuan, CCK Haltiwanger, RC Gowen, M Hwang, SM James, IE Lark, MW Rieman, DJ Stroup, GB Azzarano, LM Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF

Citation: Wh. Miller et al., Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic, J MED CHEM, 43(1), 2000, pp. 22-26

Authors: Miller, WH Bondinell, WE Cousins, RD Erhard, KF Jakas, DR Keenan, RM Ku, TW Newlander, KA Ross, ST Haltiwanger, RC Bradbeer, J Drake, FH Gowen, M Hoffman, SJ Hwang, SM James, IE Lark, MW Lechowska, B Rieman, DJ Stroup, GB Vasko-Moser, JA Zembryki, DL Azzarano, LM Adams, PC Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF

Citation: Wh. Miller et al., Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model, BIOORG MED, 9(13), 1999, pp. 1807-1812

Authors: Ward, KW Azzarano, LM Bondinell, WE Cousins, RD Huffman, WF Jakas, DR Keenan, RM Ku, TW Lundberg, D Miller, WH Mumaw, JA Newlander, KA Pirhalla, JL Roethke, TJ Salyers, KL Souder, PR Stelman, GJ Smith, BR

Citation: Kw. Ward et al., Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist, DRUG META D, 27(11), 1999, pp. 1232-1241

Authors: Lark, MW Stroup, GB Hwang, SM James, IE Rieman, DJ Drake, FH Bradbeer, JN Mathur, A Erhard, KF Newlander, KA Ross, ST Salyers, KL Smith, BR Miller, WH Huffman, WF Gowen, M

Citation: Mw. Lark et al., Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis, J PHARM EXP, 291(2), 1999, pp. 612-617

Authors: Keenan, RM Callahan, JF Samanen, JM Bondinell, WE Calvo, RR Chen, LC DeBrosse, C Eggleston, DS Haltiwanger, RC Hwang, SM Jakas, DR Ku, TW Miller, WH Newlander, KA Nichols, A Parker, MF Southhall, LS Uzinskas, I Vasko-Moser, JA Venslavsky, JW Wong, AS Huffman, WF

Citation: Rm. Keenan et al., Conformational preferences in a benzodiazepine series of potent nonpeptidefibrinogen receptor antagonists, J MED CHEM, 42(4), 1999, pp. 545-559